Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascletis In-Licenses China Rights to Second Hepatitis C Drug

publication date: Nov 10, 2014
Ascletis, a China-US novel drug developer, in-licensed China rights to a clinical-stage hepatitis C treatment from Presidio of San Francisco. PPI-668 is an NS5A inhibitor currently in a Phase II trial in the US. Ascletis is also developing another treatment for HCV: a Roche protease inhibitor known as danoprevir. Ascletis thinks the two drugs can be combined to combat HCV in an interferon-free regimen. More details....

Stock Symbol: (VIX: ROG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital